PH12021552680A1 - Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases - Google Patents
Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseasesInfo
- Publication number
- PH12021552680A1 PH12021552680A1 PH1/2021/552680A PH12021552680A PH12021552680A1 PH 12021552680 A1 PH12021552680 A1 PH 12021552680A1 PH 12021552680 A PH12021552680 A PH 12021552680A PH 12021552680 A1 PH12021552680 A1 PH 12021552680A1
- Authority
- PH
- Philippines
- Prior art keywords
- treatment
- pharmaceutical compositions
- novel compounds
- kidney diseases
- prophylaxis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000017169 kidney disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1905711.6A GB201905711D0 (en) | 2019-04-24 | 2019-04-24 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| PCT/EP2020/061083 WO2020216740A1 (en) | 2019-04-24 | 2020-04-21 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021552680A1 true PH12021552680A1 (en) | 2022-07-04 |
Family
ID=66810218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2021/552680A PH12021552680A1 (en) | 2019-04-24 | 2020-04-21 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12383544B2 (enExample) |
| EP (1) | EP3958863B1 (enExample) |
| JP (1) | JP7543304B2 (enExample) |
| KR (1) | KR20220004111A (enExample) |
| CN (1) | CN113727711A (enExample) |
| AU (1) | AU2020263869A1 (enExample) |
| BR (1) | BR112021021117A2 (enExample) |
| CA (1) | CA3137445A1 (enExample) |
| ES (1) | ES2982398T3 (enExample) |
| GB (1) | GB201905711D0 (enExample) |
| IL (1) | IL287392A (enExample) |
| MA (1) | MA55752A (enExample) |
| MX (1) | MX2021012544A (enExample) |
| PH (1) | PH12021552680A1 (enExample) |
| SG (1) | SG11202111739VA (enExample) |
| WO (1) | WO2020216740A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025096453A1 (en) * | 2023-10-30 | 2025-05-08 | Vertex Pharmaceuticals Incorporated | Compounds for the treatment of kidney disease |
| WO2025121320A1 (ja) * | 2023-12-04 | 2025-06-12 | 国立大学法人山口大学 | 多発性嚢胞腎の予防又は治療剤 |
| TW202547458A (zh) * | 2024-03-26 | 2025-12-16 | 香港商禮邦醫藥（香港）有限公司 | 用於治療體染色體顯性多囊性腎病之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362031B2 (en) * | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| EP2464354B1 (en) * | 2009-08-10 | 2015-04-01 | The Regents of The University of California | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| TWI633887B (zh) * | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及／或治療多囊性腎臟病之藥物 |
| US10174012B2 (en) * | 2014-11-04 | 2019-01-08 | The University Of Kansas | LKB1-AMPK activators for therapeutic use in polycystic kidney disease |
| WO2017060879A1 (en) | 2015-10-09 | 2017-04-13 | AbbVie S.à.r.l. | Novel compounds for treatment of cystic fibrosis |
| PL3359541T3 (pl) * | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| EP3359539A1 (en) | 2015-10-09 | 2018-08-15 | AbbVie S.À.R.L. | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use |
| JP2020525446A (ja) * | 2017-06-21 | 2020-08-27 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 常染色体優性多発性嚢胞腎疾患を治療するための嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子 |
-
2019
- 2019-04-24 GB GBGB1905711.6A patent/GB201905711D0/en not_active Ceased
-
2020
- 2020-04-21 US US17/605,623 patent/US12383544B2/en active Active
- 2020-04-21 CN CN202080030725.9A patent/CN113727711A/zh active Pending
- 2020-04-21 KR KR1020217038004A patent/KR20220004111A/ko not_active Withdrawn
- 2020-04-21 AU AU2020263869A patent/AU2020263869A1/en not_active Abandoned
- 2020-04-21 EP EP20721493.3A patent/EP3958863B1/en active Active
- 2020-04-21 MX MX2021012544A patent/MX2021012544A/es unknown
- 2020-04-21 CA CA3137445A patent/CA3137445A1/en active Pending
- 2020-04-21 PH PH1/2021/552680A patent/PH12021552680A1/en unknown
- 2020-04-21 MA MA055752A patent/MA55752A/fr unknown
- 2020-04-21 BR BR112021021117A patent/BR112021021117A2/pt not_active Application Discontinuation
- 2020-04-21 WO PCT/EP2020/061083 patent/WO2020216740A1/en not_active Ceased
- 2020-04-21 JP JP2021562854A patent/JP7543304B2/ja active Active
- 2020-04-21 ES ES20721493T patent/ES2982398T3/es active Active
- 2020-04-21 SG SG11202111739VA patent/SG11202111739VA/en unknown
-
2021
- 2021-10-19 IL IL287392A patent/IL287392A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220004111A (ko) | 2022-01-11 |
| SG11202111739VA (en) | 2021-11-29 |
| GB201905711D0 (en) | 2019-06-05 |
| BR112021021117A2 (pt) | 2021-12-14 |
| IL287392A (en) | 2021-12-01 |
| JP2022529814A (ja) | 2022-06-24 |
| CN113727711A (zh) | 2021-11-30 |
| AU2020263869A1 (en) | 2021-12-23 |
| JP7543304B2 (ja) | 2024-09-02 |
| EP3958863B1 (en) | 2024-07-03 |
| CA3137445A1 (en) | 2020-10-29 |
| MX2021012544A (es) | 2021-11-12 |
| US12383544B2 (en) | 2025-08-12 |
| US20220202802A1 (en) | 2022-06-30 |
| MA55752A (fr) | 2022-03-02 |
| EP3958863C0 (en) | 2024-07-03 |
| ES2982398T3 (es) | 2024-10-16 |
| EP3958863A1 (en) | 2022-03-02 |
| WO2020216740A1 (en) | 2020-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202403426B (en) | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| EP4374858A3 (en) | Benzimidazolone derived inhibitors of bcl6 | |
| PH12020550230A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| HK1215256A1 (zh) | 用作吲哚胺2，3-二氧化酶的抑制劑的化合物 | |
| PH12021552375A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| CY1111327T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος | |
| PH12021552377A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| ZA202400821B (en) | Inhibitors of transglutaminases | |
| PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease | |
| WO2020016847A3 (en) | Purification process for preparation of eribulin and intermediates thereof | |
| PH12021552376A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| ZA202400823B (en) | Inhibitors of transglutaminases | |
| MX2021012544A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales. | |
| EA202090750A1 (ru) | Производные глюконовой кислоты для применения в лечении и/или предупреждении инфекций, вызываемых микроорганизмами | |
| MX2025006291A (es) | Metodos de tratamiento de trastornos neurologicos | |
| EP4620940A3 (en) | Synthesis of (+)-cannabinoids and their therapeutic effects | |
| PH12021552032A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |